MTH-68/H oncolytic viral treatment in human high-grade gliomas

被引:141
作者
Csatary, LK
Gosztonyi, G
Szeberenyi, J
Fabian, Z
Liszka, V
Bodey, B
Csatary, CM
机构
[1] United Canc Res Inst, Alexandria, VA 22307 USA
[2] Free Univ Berlin, Univ Clin Benjamin Franklin, Dept Neuropathol, D-1000 Berlin, Germany
[3] Univ Pecs, Sch Med, Dept Med Biol, Pecs, Hungary
[4] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA
[5] Childrens Hosp, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
关键词
apoptosis; chemotherapy; glioblastoma multiforme (GBM); high-grade glioma; MTH-68/H; Newcastle disease virus (NDV); programmed cell death (PCD); virus therapy;
D O I
10.1023/B:NEON.0000021735.85511.05
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.
引用
收藏
页码:83 / 93
页数:11
相关论文
共 61 条
[1]   Gene therapy for gliomas:: Molecular targets, adenoviral vectors, and oncolytic adenoviruses [J].
Alemany, R ;
Gomez-Manzano, C ;
Balagué, C ;
Yung, WKA ;
Curiel, DT ;
Kyritsis, AP ;
Fueyo, J .
EXPERIMENTAL CELL RESEARCH, 1999, 252 (01) :1-12
[2]  
[Anonymous], MONOGR VIROL
[3]   Amplification and overexpression of MDM2 in primary (de novo) glioblastomas [J].
Biernat, W ;
Kleihues, P ;
Yonekawa, Y ;
Ohgaki, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :180-185
[4]   Spontaneous regression of neoplasms: new possibilities for immunotherapy [J].
Bodey, B .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (05) :459-476
[5]  
Bodey B, 1997, ANTICANCER RES, V17, P1187
[6]   IMMUNOPHENOTYPING OF CHILDHOOD ASTROCYTOMAS WITH A LIBRARY OF MONOCLONAL-ANTIBODIES [J].
BODEY, B ;
ZELTZER, PM ;
SALDIVAR, V ;
KEMSHEAD, J .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (06) :1079-1087
[7]  
Bodey B, 1999, INT J PEDIAT HEM ONC, V6, P65
[8]  
BULLARD DE, 1986, SEMIN ONCOL, V13, P94
[9]   Malignant gliomas. [J].
Burton E.C. ;
Prados M.D. .
Current Treatment Options in Oncology, 2000, 1 (5) :459-468
[10]   THE BIOLOGY OF ASTROCYTOMA - LESSONS LEARNED FROM CHRONIC MYELOGENOUS LEUKEMIA - HYPOTHESIS [J].
CAIRNCROSS, JG .
JOURNAL OF NEURO-ONCOLOGY, 1987, 5 (02) :99-104